explore -WSS

explore

author：focus 2025-08-26 02:44:20 - browse：3144

Novo Nordisk headquarters -- health coverage from STAT — Novo Nordisk's headquarters, outside Copenhagen, Denmark. LISELOTTE SABROE/Scanpix/AFP via Getty Images

Novo Nordisk is pausing ads for its obesity drug Wegovy as it struggles to keep up with surging demand, the latest hurdle in its rollout of the weight loss drug.

“To avoid stimulating further demand for this medicine, we’re pausing some key Wegovy promotional efforts,” the Danish drugmaker said in an emailed statement. “We are pausing all local television advertising and postponing planned national television advertising for Wegovy. We are also assessing our promotional efforts to healthcare professionals and adjusting accordingly.” The news was earlier reported by Endpoints.

Wegovy, which contains the active ingredient semaglutide, has become immensely popular for its effectiveness in helping people lose weight and is helping usher in what many see as a sea change in obesity treatment. Its sister drug for diabetes, Ozempic, has also been in demand for a similar effect on weight loss.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： Former Georgia lieutenant governor says he received grand jury subpoena

WSS

STAT Readout Newsletter: Biotech news today

ADCs take center stage as promising cancer treatments

Harvard's Jason Buenrostro wins MacArthur grant for genetics work

Merck, Daiichi strike cancer drug pact worth up to $22 billion

Lessons Learned: This is why you network to find that industry job you want

'Of course' Trump lost the 2020 election, DeSantis says after years of hedging

focus

explore

Wikipedia

United colonoscopy coverage change 'may cost lives,' doctors say

Former Georgia lieutenant governor says he received grand jury subpoena

Moonlake's readout produced a cash windfall. Risks remain

UnitedHealth, Optum discontinue NaviHealth name

The high cost of giving birth even with insurance

Hospitals use virtual reality to design more inclusive rooms for kids

Bright Health sells Medicare Advantage business to Molina

STAT Summit: Meghan O’Rourke on making chronic illness visible

In age of alternative facts, a scholarly course on calling out crap

STAT Readout Newsletter: Biotech news today

leisure time

Merck, Daiichi strike cancer drug pact worth up to $22 billion

Zapping the brain for stroke rehab: Pivotal clinical trial begins

STAT Summit: Ending the crisis of Black deaths in the U.S.

STAT Summit: How researchers deal with rejection

Biden praises World Series champion Astros for impact off the field during White House celebration

Sage's campaign to raise awareness of postpartum depression hits a nerve

hotspot

focus

hotspot

focus